Myopia (or nearsightedness) is becoming a global epidemic, including in Canada where children are developing the condition at a young age. Since the highly anticipated Canadian launch of CooperVision’s MiSight® 1 day contact lens during a live webinar in January, interest among the nation’s eye care practitioners (ECPs) has been accelerating.
“MiSight® 1 day is truly a unique product that stands above the crowd,” says Teresa Yu, Marketing Manager for 1 Day Brands.
Since the launch, reaction from Canadian ECPs has been overwhelmingly positive and Canada has surpassed its initial sales projections, propelling it to third in global sales of MiSight®. Demand for the product has grown significantly since the webinar was made available on-demand for ECPs unable to attend the live event.
The webinar is still capturing the attention of Canadian ECPs. During the webinar, Dr. Deborah Jones, lead clinical scientist at the Centre for Ocular Research & Education (CORE) at the University of Waterloo, shares her insight on the myopia epidemic. Formerly the Centre for Contact Lens Research, CORE is one of three sites used to conduct clinical research for MiSight® 1 day. Then, Dr. Elizabeth Lumb, European Professional Services Manager for CooperVision, explores the benefits of MiSight® in improving eyesight for people with myopia.
Following the webinar and a short quiz, ECPs were immediately able to order MiSight® 1 day lenses, along with a marketing kit aimed at patients with myopia and their families.
Canadian team leaders say the U.K. team was instrumental in helping to successfully launch MiSight® 1 day, with guidance from Stuart Cockerill and Elizabeth Lumb. The team is also grateful to the Delta Park Distribution Team for helping to overcome sourcing and delivery challenges prior to the launch.
Later this summer, another webinar on myopia management will educate Canadian ECPs on how to engage patients and families on myopia progression, and how their practices can help.
MiSight® is only approved for sale under the CE mark and in Canada, Australia, New Zealand, Hong Kong, Singapore and Malaysia.